Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

07/07/2026 Eastern Time in USA The Dow Jones Industrial Average dropped by 0.25%, closing at 52925.15 points; the Nasdaq Composite dropped by 1.16%, closing at 25818.69 points; the S&P 500 Index dropped by 0.45%, closing at 7503.85 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

CRINETICS PHARMACEUTICALS, INC.: Overnight gain 98.7%, Surges Amid Vertex Pharmaceuticals' Acquisition Offer at Significant Premium

**Crinetics Pharmaceuticals, Inc. – Company Overview** Crinetics Pharmaceuticals, Inc. was incorporated under the laws of the State of Delaware on November 18, 2008. The Company is a clinical-stage pharmaceutical enterprise focused on the discovery, development, and commercialization of novel therapeutics targeting rare endocrine disorders and endocrine-related tumors. The endocrine system mediates peptide hormone signaling through G protein-coupled receptors (GPCRs), playing a critical role in maintaining physiological homeostasis and regulating a broad range of biological processes, including growth, metabolism, gastrointestinal function, and stress response.

**CRINETICS PHARMACEUTICALS, INC. (CRNX) Surges 98.7% Following Vertex Pharmaceuticals' $10 Billion Acquisition Announcement** Shares of CRINETICS PHARMACEUTICALS, INC. (CRNX) skyrocketed 98.7% after Vertex Pharmaceuticals announced a definitive agreement to acquire the company at $85.00 per share in cash, representing a total equity value of approximately $10 billion — a premium of over 100% to Monday's closing price. The transaction has received unanimous approval from the boards of directors of both companies and is expected to close in the third quarter of 2025. The acquisition centers on two key assets: PALSONIFY, an FDA-approved oral therapy for acromegaly, and atumelnant, currently in Phase III clinical development. Vertex projects combined peak annual sales exceeding $5 billion for both assets, with the transaction expected to be accretive to operating income before 2029, providing robust financial justification for the substantial acquisition premium.

SkinHealth Systems Inc. Class A: Overnight gain 47.0%, Surges Amid FDA Approval Expanding SkinStylus Indications, Strengthening Competitive Moat

**SkinHealth Systems Inc. Company Overview** SkinHealth Systems Inc., incorporated in the State of Delaware on July 8, 2020, is an emerging enterprise operating within the aesthetic technology sector. The Company is dedicated to delivering comprehensive skin health solutions designed to reshape consumer perceptions of skin care, physical wellness, and personal confidence. The Company's core business encompasses the design, research and development, manufacturing, marketing, and commercialization of aesthetic technologies and related products. Leveraging a globally integrated network of beauty professionals, strategic partners, and consumer communities, SkinHealth Systems Inc. provides personalized skin health services tailored to individuals across diverse age groups, genders, skin tones, and skin types.

**SkinHealth Systems Inc. Class A (SKIN) Shares Rally on FDA Label Expansion for SkinStylus Device** Shares of SkinHealth Systems Inc. Class A (SKIN) surged following a key regulatory catalyst: the U.S. Food and Drug Administration (FDA) approved a new periorbital wrinkle indication for the company's SkinStylus microneedling device. This clearance positions the SkinStylus SteriLock Microsystem as the only microneedling device on the market simultaneously cleared for facial acne scars, periorbital wrinkles, and abdominal scars — materially strengthening the company's competitive moat. Meanwhile, the ongoing integration of HydraFacial combination treatment protocols continues to drive broader market penetration within the microneedling therapy segment, underscoring meaningful product ecosystem synergies. The latest FDA endorsement further validates SkinHealth Systems Inc. Class A's (SKIN) science-driven innovation strategy, bolstering investor confidence in the company's long-term positioning within the professional aesthetics sector.

Veraxa Biotech AG: Overnight gain 38.4%, Surges Amid BiTAC® Program Launch, ATUM Partnership, and Positive Preclinical Data

**Veraxa Biotech AG Formally Incorporated Under Swiss Law, Advancing Oncology Pipeline with Proprietary ADC and T-Cell Engager Platforms** Veraxa Biotech AG was formally incorporated under Swiss law on June 25, 2025, establishing itself as a clinical-stage biotechnology company focused on oncology. The company currently maintains an active clinical program in acute myeloid leukemia (AML) and holds proprietary platform technologies designed for the development of antibody-drug conjugates (ADCs) and T-cell engagers. Veraxa Biotech AG is committed to building a robust oncology product pipeline aimed at delivering superior patient outcomes while minimizing adverse side effects.

**Veraxa Biotech AG (VRXA) Surges 38.4% on Strategic Milestones and Pipeline Progress** Shares of Veraxa Biotech AG (VRXA) rallied 38.4% in a single session, driven by a confluence of positive catalysts. The company announced the initiation of cell line development for its core BiTAC® T-cell engager program, alongside a strategic collaboration with ATUM, a recognized leader in bioengineering. The partnership introduces ATUM's proprietary Leap-In Transposase® technology — which has supported more than 50 IND submissions — covering the full spectrum of CMC development workflows. These developments were further reinforced by encouraging preclinical data previously disclosed at the AACR Annual Meeting, as well as a clearly defined strategic target set by the CEO to advance VXA-102 to IND/CTA submission readiness by early 2028. The simultaneous release of multiple positive catalysts significantly bolstered investor confidence, fueling the sharp single-day price appreciation.

Agios Pharmaceuticals, Inc.: Overnight gain 17.7%, Surges Amid FDA Priority Review Acceptance and Analyst Target Price Upgrades

**Agios Pharmaceuticals, Inc.** was incorporated under the laws of the State of Delaware on August 7, 2007. The Company is a biopharmaceutical enterprise specializing in cellular metabolism, with a core strategic focus on rare diseases and a primary emphasis on classical hematology. Agios is committed to the research and development of differentiated, innovative therapeutics designed to address significant unmet medical needs and enhance the quality of life for patients living with these conditions.

**Agios Pharmaceuticals, Inc. (AGIO) Shares Surge on FDA Priority Review Designation and Analyst Upgrades** Shares of Agios Pharmaceuticals, Inc. (AGIO) rallied sharply, driven by multiple converging catalysts. The U.S. Food and Drug Administration formally accepted the company's supplemental New Drug Application (sNDA) for its lead asset mitapivat in sickle cell disease, granting Priority Review designation with a PDUFA target action date of November 1, 2026. The submission is underpinned by robust data from the Phase 2/3 RISE UP clinical trial. This development further strengthens mitapivat's commercial profile, which has already secured regulatory approvals for pyruvate kinase deficiency and thalassemia. Adding to the positive momentum, BofA Securities raised its price target on AGIO from $40 to $46, while Truist Securities lifted its target from $36 to $41, with both firms maintaining **Buy** ratings. The confluence of regulatory progress and bullish analyst sentiment propelled the stock meaningfully higher.

Inventiva SA ADR: Overnight gain 16.9%, Surges Driven by Lanifibranor Phase 3 Progress and FDA Breakthrough Designation

**Inventiva S.A. Company Overview** Inventiva S.A., incorporated in 2011 and formally registered in 2016, is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The Company's lead product candidate, lanifibranor, is a pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist that has received both Breakthrough Therapy Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA), and is currently advancing through Phase 3 clinical development.

**Inventiva SA ADR (IVA) Surges 16.9% on Clinical Pipeline Momentum** Shares of Inventiva SA ADR (IVA), a clinical-stage biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH), surged 16.9% in a single session, driven primarily by milestone progress in its Phase 3 clinical pipeline. The rally is characteristic of an event-driven move, likely tied to specific catalysts such as clinical data readouts or regulatory developments surrounding its lead asset, lanifibranor — which has received both FDA Breakthrough Therapy Designation and Fast Track status. Notably, despite the sharp single-day gain, Inventiva SA ADR (IVA) remains down approximately 1.9% year-to-date, suggesting the advance represents a targeted revaluation rather than broad momentum buying. Additionally, the continued heating of the MASH therapeutic sector has provided meaningful sector-rotation tailwinds, offering incremental support to the company's ongoing valuation recovery.

Immix Biopharma, Inc.: Overnight gain 15.0%, Surges Amid NXC-201 Clinical Progress and CAR-T Sector Momentum

**Immix Biopharma, Inc. – Company Overview** Immix Biopharma, Inc., incorporated in the State of Delaware on January 7, 2014, is a clinical-stage biopharmaceutical company specializing in chimeric antigen receptor cell therapy (CAR-T). The Company's primary research focus encompasses light chain amyloidosis (AL) and autoimmune diseases. The Company's lead cell therapy candidate, NXC-201, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) and is currently being evaluated in the Phase 1b/2a NEXICART-1 clinical trial (NCT04720313).

**Immix Biopharma, Inc. (IMMX) Surges on Clinical Milestone and Sector Momentum** Shares of Immix Biopharma, Inc. (IMMX) have posted notable gains, driven by a confluence of catalysts. The company's lead pipeline candidate, **NXC-201**, a CAR-T cell therapy, has demonstrated meaningful progress in the **NEXICART-1 Phase 1b/2a clinical trial**, serving as the primary catalyst underpinning investor confidence. Immix Biopharma, Inc. (IMMX) maintains a differentiated positioning within the **light chain amyloidosis and autoimmune disease** segment — a niche therapeutic area characterized by limited competition — commanding a scarcity premium among investors. Additionally, broader sector tailwinds from heightened enthusiasm surrounding CAR-T therapeutics have amplified the stock's upward momentum. The overnight single-session gain of approximately **15%** reflects the concentrated release of multiple positive factors, while the **129.8% year-to-date cumulative return** underscores sustained market recognition of the company's advancing research and development trajectory.

Alight, Inc. Class A: Overnight gain 13.9%, Surges Amid Technical Rebound, Strong Client Base, and Digital Transformation Tailwinds

**Alight, Inc. Class A | Company Overview** Alight, Inc. was incorporated in the State of Delaware on September 12, 2018, and stands as a leading provider of integrated cloud-based human capital solutions, dedicated to empowering employers and their workforces in managing health, wealth, and human resources needs. Underpinned by more than 25 years of operational history and deep domain expertise, the Company is well-positioned to address the complex demands of large enterprises and their diverse employee populations. Alight's client base currently spans nearly 3,000 employers, including 66 Fortune 100 companies and 240 Fortune 500 enterprises, underscoring its strong market penetration across blue-chip corporate clientele. The Company provides comprehensive support to approximately 22 million active and former employees, as well as 18 million dependents and family members. In fiscal year 2017, Alight processed in excess of 340 million benefits and human resources transactions, reflecting the scale and operational depth of its platform and reinforcing its position as a mission-critical partner in the human capital management landscape.

**Alight, Inc. Class A (ALIT) Surges 13.9%, Ranks Among Top Gainers on U.S. Equities Market** Shares of Alight, Inc. Class A (ALIT) posted a notable single-day gain of 13.9% as of the market close on July 6, 2026 (ET), ranking sixth among the top ten best-performing U.S. equities for the session. The rally appears driven by a confluence of factors. First, ALIT had accumulated a year-to-date decline of approximately 51.2%, compressing its market capitalization to an estimated range of $449 million to $511 million, creating compelling conditions for a technical rebound. Second, the company's deep-rooted client relationships — serving 66 Fortune 100 and 240 Fortune 500 enterprises across 22 million beneficiaries — highlight a significant disconnect between current valuation and underlying business scale, attracting value-oriented capital inflows. Third, as a leading provider of cloud-based human capital solutions, Alight, Inc. Class A (ALIT) stands to benefit from accelerating enterprise digital transformation trends, driving broader sector re-rating momentum.

Neurogene Inc.: Overnight gain 13.0%, Surges Amid Successful Public Equity Offering, Strong Institutional Demand Extends Cash Runway

**Neurogene Inc. Company Background** Neurogene Inc. was originally incorporated in the state of Delaware in May 2007 under the name Aquinox Pharmaceuticals. Following a series of mergers and corporate reorganizations, the company formally adopted its current name in December 2023. Neurogene is a clinical-stage biopharmaceutical company focused on the development of gene therapies targeting rare neurological disorders, leveraging its proprietary EXACT transgene regulation technology platform.

**Neurogene Inc. (NGNE) Shares Surge 13.0% Following Successful $125 Million Public Equity Offering** Shares of Neurogene Inc. (NGNE) rallied sharply, driven by the company's successful completion of an approximately $125 million public equity offering. The clinical-stage gene therapy company priced 3.5 million shares of common stock at $30.00 per share, alongside the issuance of 666,666 immediately exercisable pre-funded warrants to select investors. Net proceeds, after deducting underwriting fees and expenses, totaled approximately $134.8 million, extending the company's cash runway through Q1 2029. Notably, underwriters exercised their overallotment option in full, acquiring an additional 624,999 shares — a strong signal of robust institutional demand. The strengthened balance sheet positions Neurogene Inc. (NGNE) to advance its core pipeline targeting rare neurological diseases. Market confidence surged in response, propelling shares up 13.0% in a single session, bringing year-to-date gains to 78.6%.

Invivyd: Overnight gain 12.9%, Surges Amid FDA Regulatory Milestone for PEMGARDA Commercial Approval Pathway

**Invivyd, Inc. — Company Overview** Incorporated in the State of Delaware in June 2020, Invivyd, Inc. is a commercial-stage biopharmaceutical company focused on the development of antibody-based therapeutics designed to protect vulnerable populations against epidemic viruses, with SARS-CoV-2 serving as the foundational area of research. The Company's proprietary technology platform, INVYMAB, integrates cutting-edge viral surveillance capabilities, predictive modeling, and antibody engineering expertise, enabling the rapid and continuous development of novel monoclonal antibodies to address the ongoing threat posed by continuously evolving viral variants.

**Invivyd (IVVD) Shares Surge 12.9% on FDA Regulatory Milestone for PEMGARDA** Shares of Invivyd (IVVD) rallied 12.9% in a single session following a significant regulatory development. On July 6, 2026, the company announced receipt of formal FDA notification indicating plans to advance its core antibody asset, PEMGARDA, along a post-Emergency Use Authorization (EUA) approval pathway. This development signals a potential transition from emergency use status toward full commercial approval, which market participants interpreted as a critical milestone, directly catalyzing the intraday price surge. Further reinforcing management's confidence in the company's trajectory, Invivyd (IVVD) granted a total of 493,000 stock options to 14 newly hired employees on July 1, underscoring continued organizational investment and long-term growth conviction. Despite the positive momentum, Invivyd (IVVD) shares remain down approximately 61.9% on a year-to-date basis, though the latest regulatory catalyst has meaningfully improved near-term market sentiment.

Precision BioSciences: Overnight gain 12.3%, Surges Amid Breakthrough Progress in Hepatitis B Gene Editing Program

**Precision BioSciences, Inc.** is a Delaware-incorporated advanced genomic editing company that leverages its proprietary ARCUS® platform to develop in vivo gene editing therapeutics, with a focus on complex genomic engineering applications encompassing gene disruption, insertion, and excision.

**Precision BioSciences (DTIL) Surges 12.3% on Hepatitis B Gene Editing Program Breakthrough** Shares of Precision BioSciences (DTIL) surged 12.3% in a single trading session, driven by a pivotal announcement regarding significant advancements in the company's hepatitis B gene editing program, which served as the direct catalyst for the sharp intraday rally. As a biotechnology company specializing in gene editing therapeutics, Precision BioSciences (DTIL) has continued to advance its research pipeline, prompting an overwhelmingly positive market response to the commercialization prospects of its proprietary technology platform. The latest favorable disclosure further reinforced investor confidence in the company's R&D pipeline progression, building upon an already impressive year-to-date cumulative gain of 122.4%. The announcement has meaningfully strengthened market sentiment surrounding Precision BioSciences (DTIL)'s long-term growth trajectory, sustaining upward momentum in the company's share price.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team. Risk and Disclaimer: The content provided above is solely for informational purposes and does not represent the views or positions of Sahm Platform. While we strive for accuracy, we cannot guarantee the authenticity or completeness of the information contained in the provided content. We strongly recommend that investors consult with a qualified investment advisor when deemed necessary. Sahm Platform neither provides investment advice nor makes any representations or warranties concerning the accuracy, reliability, or completeness of the information in the content provided above. By using Sahm Platform, you acknowledge that you have read, understood, and agreed to the terms set forth in this disclaimer.